- Termination of Registration of a Class of Security under Section 12(g) (15-12G)
11 Maggio 2012 - 10:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 001-32581
LOTUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Nevada
|
|
20-0507918
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
16 Cheng Zhuang Road, Feng Tai District, Beijing 100071
People’s Republic of China
86-10-63899868
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.001
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
|
|
|
|
|
|
Rule 12g-4(a)(1)
|
x
|
Rule 15d-6
|
o
|
|
|
|
Rule 12g-4(a)(2)
|
o
|
|
|
|
|
|
Rule 12h-3(b)(1)(i)
|
o
|
|
|
|
|
|
Rule 12h-3(b)(1)(i)(ii)
|
o
|
|
|
|
|
|
|
|
|
|
|
|
Approximate number of holders of record as of the certification or notice date:
|
77
|
Pursuant to the requirements of the Securities Exchange Act of 1934, Lotus Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
DATE:
|
May 11, 2012
|
|
By:
|
/s/ Liu Zhongyi
|
|
|
|
|
Liu Zhongyi
|
|
|
|
|
Chief Executive Officer
|
Grafico Azioni Lotus Pharmaceuticals (PK) (USOTC:LTUS)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lotus Pharmaceuticals (PK) (USOTC:LTUS)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Lotus Pharmaceuticals Inc (PK) (OTCMarkets): 0 articoli recenti
Più Articoli Notizie